Cameron Forni Pushes Innovation With Rolling Stone Cannabis Collab

Pulling up to entrepreneur turned cannabis mogul Cameron Forni’s Las Vegas home feels like driving up to the entrance of a Las Vegas Strip hotel. In his driveway, a custom-decalled Ferrari stands out with a monopoly-esque art themed wrap. The wrap showcases his consulting company, an eco-friendly crypto currency, and also pays homage to the brand that started it all—Select. Parked next to it is an all-black Rolls Royce Ghost. On first impression, Cameron Forni has built quite a life as an entrepreneur.  

“I’m glad you found the house!” He says jokingly as I hop out of my car and walk up his impressive driveway to the door. The 35-year-old can’t be any taller than 5-foot-9, and his unassuming black t-shirt and navy-blue shorts suggest that, even with this level of success, he’s still relatable.

We are greeted by a pair of medium-sized Pomsky’s, Meso and Cali. We make our way through the striking entryway to the kitchen where we all sit together to become more acquainted. Forni passes around a plate of avocado toast for us to snack on while we discuss his latest device for Select in the cannabis space.  

We’re here to talk about the recent partnership Select launched with Rolling Stone magazine on co-branded vape pens and Select’s first-ever pre-rolls. Forni explains that his goal is to create a smooth, enjoyable experience for all cannabis users. Further, he is excited about the reach and cultural alignment between the Rolling Stone brand and music. 

Rolling Stone’s president and COO Gus Wenner also speaks to the larger purpose driving the new co-branded product line.  

“There’s a mission here that’s been a part of our DNA since the beginning. Music and cannabis are so connected, and we set out to make a product that is A) really good and B) strikes right at the heart of what makes experiencing great music so special,” Wenner told Cannabis Now, adding that the Rolling Stones team has spent the past three years exploring ways to create this opportunity.

“In CuraLeaf and Select, we found a perfect partner who could design innovative and exciting products that elevate the music listening experience and so much more,” he said. “We both recognize cannabis’ place in music and in history. We’ve covered the health benefits and some of the incarceration issues around how cases are treated for non-violent crime offenders in our reporting and will continue to do so.”

If legal cannabis was a baseball game, Forni insists we’d still be in the second inning of a typical nine-inning game. The black market remains too powerful for the legal industry to reach its full potential, he says. Forni also comments on the tumultuous hemp-based Delta-8 market, which he believes “is finally being cracked down on.” 

The Select founder contends legal weed’s biggest boon will happen when Congress passes the SAFE Banking Act and the STATES Act, opening the way for cannabis companies to list on the New York Stock Exchange. 

“It’ll change the entire financial landscape of the cannabis industry,” he says. “That’s what we’re waiting for.” 

The legal cannabis Green Rush has been good to entrepreneurs like Forni, who got involved early and worked tooth-and-nail to earn significant market share. Forni founded Select back in 2015 after puffing on a marijuana vape and coughing his lungs out. This experience inspired his first business venture, and he set out to develop a smoother cartridge. Select was born. 

Forni built this company from the ground up and filled his first cartridges by hand. From his living room, Forni managed to turn Select into the fastest growing cannabis brand in history. This caught the attention of the world’s largest cannabis company, Curaleaf, which purchased his company for $948 million dollars in 2019. Since the sale, Forni has stayed on as a special advisor to Curaleaf’s CEO Joe Bayern. Expanding the product line beyond its staple cartridge products, Select now also offers THC oil, gummies, tinctures and drink mixers.

Forni brings us to his office and hands over a pack of his newest edibles, “Nano Gummies.” The citrus-flavored edible is made of strain-inspired terpene formulas and are infused with cannabis oil. They are also water soluble which allows the THC to digest quicker. Their new gummies will surely be a hit across the 2,000 dispensaries in 21 states that carry Select’s products. However, Forni isn’t completely satisfied quite yet. “You can taste hints of cannabis, we can make it better,” he says. 

How does a guy in Forni’s position not let all of this get to his head? We ask him how he’s changed, besides the new house and luxury lifestyle. The answer? Not much. Forni says he’s always had a bit of an edge to him. But in a good way. 

“You got to keep it,” he says of his ego. “I always try to be myself; I always try to be kind to everyone around me, and I always try to teach and mentor people to bring them up to the next level. Success follows success, and I always wanted to follow the people that had success before me. I just hope I can inspire people—whether that’s a role model or a mentor—to do and achieve incredible things for themselves, their family and the planet.”  

The post Cameron Forni Pushes Innovation With Rolling Stone Cannabis Collab appeared first on Cannabis Now.

B Noble to Expand to Six States and Enlist Gallery PR

Last July, hip-hop historian, artist and filmmaker Fred “Fab 5 Freddy” Brathwaite and former prisoner Bernard Noble launched B Noble, a symbolic cannabis brand sold in two-joint packs—the same amount of cannabis that initially led to Noble’s inhuman prison sentence.

B Noble recently teamed up with the Latina-owned Gallery PR as an agency of record which is based in Los Angeles and New York City. B Noble also announced six new states to its list of Curaleaf locations where you can find the company’s products.

In 2010, Bernard Noble was minding his own business when he was stopped by two police officers while riding his bicycle in New Orleans. He was stopped, frisked and arrested for possession of two joints’ worth (2.8g) of weed, leading to a 13-year sentence of hard labor in a Louisiana state prison. “I was labeled as a kingpin with a $5 marijuana charge,” Noble told High Times last month.

While difficult to comprehend—hard labor is tolerated as a punishment for felony charges in Louisiana. Noble was found guilty of the state’s “habitual offender” law, leading to his sentence “at hard labor.” The Atlantic called Louisiana’s forced labor laws “American slavery, reinvented,” as even the Thirteenth Amendment forbids involuntary servitude in most cases. It was a clear-cut case of how Black people are targeted by cannabis laws despite nearly equal rates of usage, and the racist elements of prohibition that are impossible to ignore—even today.

Thankfully, Bernard’s case eventually drew attention on social media. And as a result, Bernard was released after serving seven years into his sentence. “Bernard’s case happened to be the case that I decided to focus on to show the incredible injustice of these War on Drugs, sham cannabis laws that have plagued people for 80-plus years,” Fab 5 Freddy told High Times.

B Noble’s first product, “2 Joints” symbolizes the two joints that sent Bernard to prison years ago. B Noble pre-roll packs are available now at Curaleaf dispensaries in Maryland and Massachusetts. 

In September and October, B Noble announced the products will be sold at Curaleaf stores across Arizona, Illinois, Michigan, Oregon, Colorado and Nevada. Curaleaf is “the world’s largest cannabis operator by revenue” and is B Noble’s operational partner. 

B Noble shared the core components they hope to envelop: 

  • Creating Prosperity for All
  • Education Through Storytelling 
  • Civic Outreach
  • Reparatory & Social Justice
  • Art, Music & Entertainment 
Photo courtesy B Noble Inc. and Curaleaf Holdings, Inc.

Fab 5 Freddy and B Noble

According to the New York Times, Fab 5 Freddy united the worlds of hip-hop and art decades ago. This important role of bringing Black representation to the music, art and cannabis industries has cemented Fab 5 Freddy’s legacy in America.

Street artists Fab 5 Freddy and Jean-Michel Basquiat became the first hip-hop element in a music video appearance in Blondie’s “Rapture,” debuting on Solid Gold on January 31, 1981. Subsequently, as MTV’s first hip-hop VJ and host of Yo! MTV Raps, Fab 5 Freddy brought some Black visibility to the network, after people like the late David Bowie slammed MTV for ignoring Black artists.

Because of Fab 5 Freddy’s contributions, in 2019 it was announced that Harlem, New York’s Schomburg Center for Research in Black Culture will display his priceless collection of rap memorabilia for public view at the historical uptown library.

This eventually led to the important question of why the cannabis industry often shuns Black people, sometimes over nonviolent cannabis cases—such as in the case of Noble. Freddy’s Netflix documentary Grass Is Greener explores America’s complicated relationship with cannabis and racism. But his mission wasn’t fulfilled until Fab 5 Freddy decided he needed to include former prisoners in the business, which led to his partnership with Noble.

Fab 5 Freddy, with the help of former prisoner B Noble, are here to continue to bridge the divide between Black people struggling to take part of the industry, and commercial cannabis.

The post B Noble to Expand to Six States and Enlist Gallery PR appeared first on High Times.

Rolling Stone and Curaleaf Partner On New ‘Rolling Stone by Select’ Cannabis Brand

International cannabis powerhouse Curaleaf announced on Tuesday that its Select brand will market co-branded cannabis products under a new strategic partnership with pop culture and music authority Rolling Stone. The deal will initially bring “Rolling Stone by Select” branded vaporizer products and pre-rolled joints to Nevada, with plans to expand to other regulated cannabis markets in the future.

Rolling Stone and Select are creating a groundbreaking partnership that will showcase our next generation hardware [and] America’s best-selling premium cannabis oil while curating an exclusive relationship between music, cannabis and culture,” Select founder and president Cameron Forni wrote in an electronic message to Cannabis Now.

The new line of Rolling Stone by Select products will include Select’s newest proprietary cannabis oil vaporizer pod system, The Cliq, as well as Select’s first ever pre-rolled joint. Both product formats will feature three different “strains and flavor profiles hand-selected by Rolling Stone to celebrate some of the most well-known and genre-defining artists and sounds in music history,” Curaleaf wrote in a press release. The line includes Overdrive, berry-forward sativa; a complex and full-bodied indica known as Reverb; and a fruity, calming hybrid marketed under the moniker Phaser. The products will be distributed through Select’s wholesale partners and at Curaleaf dispensaries, including Acres by Curaleaf and Curaleaf Las Vegas Boulevard.

Rolling Stone by Select Cliq Vaporizer

“Music and Cannabis go hand in hand,” said Rolling Stone president and chief operating officer Gus Wenner, noting that the company has a legacy of celebrating this connection and a history of covering cannabis policy reform efforts.

“We are thrilled to have found a perfect partner in Curaleaf who gives us the opportunity to design a product that elevates the music listening experience and celebrates the deep connection between the two.” 

Music Icon Teams with Cannabis Powerhouse

Curaleaf and Select made headlines in 2019 when they joined forces in what was at the time the cannabis industry’s largest merger deal in history. Today, Curaleaf operates in 23 states with 106 cannabis dispensaries, 23 cultivation sites, and more than 30 processing sites, with a workforce of nearly 5,000 in the United States. Curaleaf International is the largest vertically integrated cannabis company in Europe, conducting pioneering scientific research integrated with a unique supply chain including cultivation, extraction and production, as well as a distribution network across the European market. 

“Part of my job at Curaleaf is building brands people love. Select is a brand built around the relentless pursuit of progress and going to great lengths to create the best possible experience for our consumer,” Curaleaf CEO Joe Bayern said in a statement from the company. “This is a synergy we are honored to share with Rolling Stone. They are known for having one of the most authentic and discerning voices in modern journalism, and, as part of that, they’ve included cannabis in their coverage for the past 50 years – something many other publications are only just starting to do today. We’re honored and thrilled that the Rolling Stone team believes in our vision, our products and our people to create and deliver the highest-quality cannabis products and experiences in the industry.”

Putting Social Equity into Practice

Bayern told Cannabis Now in an email that Rolling Stone and Curaleaf have an opportunity to use their combined platforms to advance social equity issues including reducing mass incarceration and ensuring that all entrepreneurs, especially those belonging to communities adversely affected by the War on Drugs, have an opportunity to participate in the legal cannabis economy.

“Since our inception, Curaleaf has been dedicated to putting its best foot forward for each other, our customers and our communities. We truly believe in shaping a healthy, inclusive, well-regulated cannabis industry that provides for social, financial and environmental benefits shared by all,” Bayern said. “Throughout Curaleaf’s network and supply chain, we’re constantly looking for ways to support equal access and opportunity for communities impacted by the War on Drugs so that everyone has the chance to participate in the regulated cannabis industry.”

Bayern noted that Curaleaf’s corporate social responsibility (CSR) initiative, called “Rooted in Good,” is grounded on three core pillars: social equity; sustainability; and diversity, equity, and inclusion (DE&I). Through the program, Curaleaf strives to deliver social impact through focused efforts that match the company’s capabilities and prioritize resources for social equity programming that deliver real opportunities.

“As a part of that work, we engage in strategic partnerships activating programs that foster opportunity and remove systematic barriers for communities most harmed by the War on Drugs and cannabis criminalization,” Bayern said. “Regarding our partnership with Rolling Stone, we are excited to explore conversations with their CSR team around future endeavors to further advance cannabis social equity issues and bring about change in a positive way.”

Curaleaf also revealed that the partnership would launch a new retail concept inspired by “Select’s commitment to enriching communities and creating inclusive, meaningful experiences and Rolling Stone’s world class storytelling and culture-defining content.” The retail location is expected to open in Las Vegas in 2022, with further details to be announced later.

The post Rolling Stone and Curaleaf Partner On New ‘Rolling Stone by Select’ Cannabis Brand appeared first on Cannabis Now.

The Cannabis Business Weekly Review: U.K. Hemp Crops Destroyed, More FDA Warning Letters, Aurora’s New Contract, and more

This week we see British crops destroyed after a hemp farm butts heads with the U.K. Home Office.

And following what seemed to be a very productive public meeting between CBD industry stakeholders and the U.S. Food and Drug Administration, the FDA sent another warning letter to well-known brand CuraLeaf. Then all the way in Israel, the medical cannabis export initiative has been delayed due to internal squabbles. All that and more in this week’s Cannabis Business Weekly Review and Newsletter.

Home office crackdown sees cannabis crop destroyed

hempen

In a show of force, the U.K. Home Office is demonstrating their strict rules by withdrawing the license of Hempen, an organic farm in Oxfordshire.  The cultivators have been forced to destroy 40 acres of their hemp, costing the business over £200,000 in lost revenue. Hempen said that in their annual declaration they admitted to illegally producing CBD for trade in the U.K. market.

Click here to read the full story

Subscribe to the Cannabis Business Weekly Newsletter

Aurora’s new contract to supply Italian medical cannabis market

aurora italy

Edmonton-based Aurora announced that it was the sole winner of the Italian government’s latest contract to supply the country with medical cannabis. Aurora beat out fellow Canadian companies Tilray, Canopy, and Wayland, as well as multiple companies from different countries. Over the next two years, Aurora will supply a minimum of 400 kilogram of medical cannabis from its Canadian EU GMP certified facilities and imported to Italy through Aurora Deutschland, its wholly-owned European subsidiary, said the company.

Click here to read the full story

Subscribe to the Cannabis Business Weekly Newsletter

The FDA just issued its newest CBD warning letter, targeting CuraLeaf

curaleaf fda

In a warning letter dated July 22, 2019, The FDA addressed multiple violations being committed by the company CuraLeaf. Does that name sound familiar to you? It should. It’s the company that secured a deal with CVS to sell CBD products in the pharmacy chain earlier this year. In the letter, the FDA referred to CuraLeaf products as “unapproved and misbranded human drugs products.”

Click here to read the full story

Subscribe to the Cannabis Business Weekly Newsletter

Israeli medical cannabis exports delayed by internal politics

israel export

People were thrilled when the Israeli government approved a progressive new program to export medical cannabis to the international market. However, differences regarding who will control pricing between the officials at the Israeli Ministries of Health and Finance have delayed the recently-launched export initiative.

Click here to read the full story

Subscribe to the Cannabis Business Weekly Newsletter

U.S. Vape Shop Survival Depends on CBD

vape shops

The Vape Industry was so quickly becoming a permanent economic fixture in the global market moving too fast to control — often mislabeled as a “fad” by talking heads. However, vaping rapidly became not only a lifesaver, but also a lifestyle — and what’s considered my most to be a healthier lifestyle.

Click here to read the full story

Subscribe to the Cannabis Business Weekly Newsletter

OTHER TRENDING NEWS

Get 30% Off The PhenoPen Premium CBD Vaping Kit

LIMITED-TIME OFFER. For people who need instant relief from their pain, insomnia, or anxiety, vaping CBD can be the ultimate solution. Vaping is believed to be safer than smoking and works faster than edibles. When you come across such a high quality product as the PhenoPen, it’s a no-brainer.

Click HERE to get your PhenoPen NOW!

Subscribe to the Recreational CBD Weekly Newsletter

A guide to finding the right CBD dose

cbd dose

While the CBD industry is growing in leaps and bounds, scientific research and studies remain lacking. One thing that nobody really has a clue about is what the right CBD dose is for which condition. For the time being, there are no specific guidelines which has patients feeling confused and frustrated.

Click here to read the full story

Click here to subscribe to the Medical Cannabis Weekly Newsletter

The post The Cannabis Business Weekly Review: U.K. Hemp Crops Destroyed, More FDA Warning Letters, Aurora’s New Contract, and more appeared first on CBD Testers.

FDA Warns Curaleaf About Unproven CBD Claims; CVS Stores Pull Products

United States regulators warned a leading marijuana company for making unproven health claims about cannabidiol (CBD), an ingredient that’s turning up in lotions, foods, and pet treats.

The Food and Drug Administration (FDA) announced July 23, 2019, that it warned Curaleaf Inc., of Wakefield, Massachusetts, for illegally selling unapproved products. Curaleaf’s claims could lead people to delay medical care for serious conditions such as cancer, the agency said.

“Consumers should beware of purchasing or using any such products,” said Acting FDA Commissioner Ned Sharpless in a statement.

The FDA has issued similar warning letters to smaller businesses, but this is the first since the agency began studying how it regulates CBD. The agency plans to report in the fall on its regulatory approach after holding a public hearing and receiving nearly 4,500 comments.

The agency is exploring “potential regulatory pathways” for some CBD products to be lawfully marketed, Sharpless said.

Curaleaf, which operates in 12 states, said it will work with the FDA to resolve the issues mentioned in the warning letter. The company’s shares fell more than 7% on the news, and some other cannabis stocks lost ground.

The company “is fully committed to complying with FDA requirements for all of the products that it markets,” Curaleaf said in a statement.

CVS Health, which started carrying CBD skin products in some states in 2019, plans to remove Curaleaf from its shelves following the FDA’s warning, said CVS spokesperson Mike DeAngelis in an email. The drugstore chain has been selling Curaleaf CBD lotion and skin patches. CVS does not sell any CBD supplements or foods, DeAngelis said.

Curaleaf’s website and social media accounts show the company is illegally selling unapproved new drugs, the FDA said, specifically its CBD lotion, a pain-relief patch, several tinctures, and disposable vape pens.

The company’s Bido CBD for Pets products are unapproved animal drugs, the FDA said.

The FDA cited claims the company made for CBD’s effectiveness in treating chronic pain, anxiety, attention deficit/hyperactivity disorder (ADHD), Alzheimer’s disease, Parkinson’s disease, cancer, and opioid withdrawal.

Curaleaf said all its CBD products are derived from hemp, a version of the cannabis plant that is low in THC, the cannabinoid that gives marijuana its intoxicating high.

Hemp gained new status as an agricultural crop in late 2018 when President Donald Trump signed the 2018 Farm Bill.

The CBD industry hoped the legislation would allow broad sales of the ingredient.

But the FDA still regulates pharmaceutical products. Since CBD is the active ingredient of GW Pharmaceuticals’ Epidiolex, approved by the FDA in 2018, the agency has said it can’t be added to food or marketed to treat health conditions without going through the FDA’s established processes.

— Carla K. Johnson


Featured image: Massachusetts-based Curaleaf was warned July 23, 2019, by the U.S. Food and Drug Administration to cease making health-related claims about its cannabidiol (CBD) products. Curaleaf, which sells its products in 12 states, is set to have its products removed from CVS Health’s shelves, a spokesperson for the drugstore chain said. (David Zalubowski/Associated Press file photo)

The post FDA Warns Curaleaf About Unproven CBD Claims; CVS Stores Pull Products appeared first on Weedmaps News.

The FDA Just Issued Its Newest CBD Warning Letter, Targeting CuraLeaf

Despite pressure from congress, senate majority leaders, industry stakeholders, and even the general public – it seems the FDA is making very little headway in terms of establishing regulations for the U.S. CBD market.

In a warning letter dated July 22, 2019, The FDA addressed multiple violations being committed by the company CuraLeaf. Does that name sound familiar to you? It should. It’s the company that secured a deal with CVS to sell CBD products in the pharmacy chain earlier this year. They were set to supply select products to over 800 stores nationwide, until this happened. In a swift response to this FDA fiasco, CVS already announced that they plan to pull CuraLeaf’s existing products off store shelves.

Following news of the warning letter, CuraLeaf’s stocks immediately plummeted by around 13%, although the have began to level out again over the last few hours. When Yahoo Finance reached to the company, they responded promptly: “CuraLeaf is fully committed to complying with FDA requirements for all of the products that it markets. We can reaffirm that nothing in the letter raises any issues concerning the safety of any CuraLeaf product.”

 

So, what exactly was in that letter? It was incredibly detailed, although it’s states in the letter itself that they didn’t address all the of violations observed and the responsibility would fall solely on CuraLeaf to make sure their website is fully compliant within the next 15 days.

In the letter, the FDA referred to CuraLeaf products as “unapproved and misbranded human drugs products.” They stated that various items listed for sale on their website are considered “drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or any function of the body.”

Some of the noted medical claims include using a CBD vape pen for chronic pain and inflammation, and using CBD oil for anxiety, depression, ADHD, and other mental health disorders. Let it be known that these warnings were in reference to both products that were for sale, as well as articles on the company’s blog. To find these claims, the FDA looked CuraLeaf’s company website and all of their social media accounts.

They also addressed the labeling of CBD as a dietary supplement. As per the letter, “Information on your (CuraLeaf’s) website and social media accounts suggests that you may intend to market your CBD products as dietary supplements… However, they cannot be dietary supplements because they do not meet the definition of a dietary supplement under sections 201(ff)(3)(B) and 201(ff)(2)(A)(i) of the FD&C Act, 21 U.S.C. 321(ff)(3)(B) and 321(ff)(2)(A)(i).”

“The FDA has concluded based on available evidence that CBD products are excluded from the dietary supplement definition.”

They were also adamant about stifling claims made regarding pets and CBD. They targeted CuraLeaf’s ‘Bido CBD for Pets’ treats, as well as multiple articles which stated that CBD can benefit pets in many ways including relieving pain, minimizing anxiety, and reducing seizures. The FDA was having absolutely none of that.

“Because the products are intended to mitigate, treat, or prevent disease in animals, they are drugs within the meaning of section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B). Further, these products are “new animal drugs” under section 201(v) of the FD&C Act, 21 U.S.C. 321(v), because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act, 21 U.S.C. 360b, 360ccc, and 360ccc-l.”

In the letter, the FDA emphasized the fact that this letter is not an “all-inclusive” statement of violations, and that CuraLeaf has 15 days upon receipt to fix these and any other unlisted issues or they will face further legal action.

Follow this link to read the full letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/curaleaf-inc-579289-07222019

The post The FDA Just Issued Its Newest CBD Warning Letter, Targeting CuraLeaf appeared first on CBD Testers.

Wednesday, July 24, 2019 Headlines | Marijuana Today Daily News

Marijuana Today Daily Headlines
Wednesday, July 24, 2019 | Curated by host Shea Gunther

// Senate Hearing Represents A Step Toward Providing Marijuana Banking Access (Marijuana Moment)

// FDA Warns Curaleaf about CBD Marketing Claims (New Cannabis Ventures)

// Juneau Assembly OKs onsite pot smoking (Peninsula Clarion)


Today’s headlines are brought to you by our friends over at Eaze.com, California’s top one stop website for legal marijuana delivery. If you live in the golden state, swing over to Eaze.com to see if they are active in your area. With deliveries taking place in less than an hour, it’s never been easier to get legal California marijuana delivery. And of course, if you don’t live where Eaze delivers, you can still benefit from all the useful bits of industry insight and analysis they’ve developed using their properly aggregate and anonymized sales data stream.


// Marijuana companies protest Utah’s medical pot grower picks (St George News (AP))

// Some NC lawmakers want to ban smokable hemp. It looks too much like marijuana, they say. (Charlotte Observer)

// This Luxury Home Developer is Designing ‘Marijuana Mansions’ for Elite Cannabis Consumers (Civilized)

// Cory Booker Slams Joe Biden’s Marijuana And Criminal Justice Proposal As Inadequate (Marijuana Moment)

// It’s Getting Harder to Fire People for Using Pot (Bloomberg Businessweek)

// AZ Attorney General Wants Lawmakers to Legalize Cannabis, Not Voters (AZ Marijuana)

// Chart: Hawaii’s medical cannabis reciprocity program off to slow start (Marijuana Business Daily)


Check out our other projects:
Marijuana Today— Our flagship title, a weekly podcast examining the world of marijuana business and activism with some of the smartest people in the industry and movement.
Marijuana Media Connect— A service that connects industry insiders in the legal marijuana industry with journalists, bloggers, and writers in need of expert sources for their stories.

Love these headlines? Love our podcast? Support our work with a financial contribution and become a patron.

Photo: Ken Lund/Flickr

Thursday, July 18, 2019 Headlines | Marijuana Today Daily News

Marijuana Today Daily Headlines
Thursday, July 18, 2019 | Curated by host Shea Gunther

// U.S. Weed Leader Curaleaf Surges on $875 Million Deal (Bloomberg)

// ‘Breakdown’ in Washington state traceability system update costs cannabis businesses thousands (Marijuana Business Daily)

// Utah drops residency restriction for medical cannabis growers (Marijuana Business Daily)


Today’s headlines are brought to you by our friends over at Eaze.com, California’s top one stop website for legal marijuana delivery. If you live in the golden state, swing over to Eaze.com to see if they are active in your area. With deliveries taking place in less than an hour, it’s never been easier to get legal California marijuana delivery. And of course, if you don’t live where Eaze delivers, you can still benefit from all the useful bits of industry insight and analysis they’ve developed using their properly aggregate and anonymized sales data stream.


// Senate Schedules Second Cannabis Hearing For Next Week (Marijuana Moment)

// California government report finds regulators are unable to fully oversee the state’s marijuana market (Marijuana Business Daily)

// The DEA Seized Fewer Plants But Made More Pot Arrests in 2018, Report Says (Merry Jane)

// Disney World Fires Bartender for Using CBD Oil to Treat Foot Pain (Merry Jane)

// Bipartisan lawmakers offer federal bill to break medical marijuana research logjam (Marijuana Business Daily)

// Thousands Of Comments Urge FDA To Allow CBD In Foods And Supplements (Marijuana Moment)

// Does an oyster festival donation help a marijuana company comply with state law? Regulators say no. (Mass Live)


Check out our other projects:
Marijuana Today— Our flagship title, a weekly podcast examining the world of marijuana business and activism with some of the smartest people in the industry and movement.
Marijuana Media Connect— A service that connects industry insiders in the legal marijuana industry with journalists, bloggers, and writers in need of expert sources for their stories.

Love these headlines? Love our podcast? Support our work with a financial contribution and become a patron.

Photo: Conor Lawless/Flickr